RUGIATU BAHR: Open Payments
NPI 1861958472 · NEWNAN, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,254 in 40 payments from 12 companies in 2025. Trend: 2023 $1,529 · 2024 $1,421 · 2025 $1,254
Food & beverage: $1,155Education: $100
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 19 | $348 |
| Vanda Pharmaceuticals Inc. | 5 | $198 |
| Neurocrine BioSciences, Inc. | 3 | $170 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $137 |
| Janssen Pharmaceuticals, Inc | 1 | $133 |
| Axsome Therapeutics, Inc. | 2 | $99 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Alkermes, Inc. | 2 | $39 |
| E.R. Squibb & Sons, L.L.C. | 1 | $27 |
| Luye Pharma (USA) Ltd. | 1 | $25 |
Products named: FANAPT, INGREZZA, UZEDY, CAPLYTA, INVEGA SUSTENNA, Auvelity, AUSTEDO XR, ARISTADA.
Industry payments across GA — which companies pay providers there.
